Introduction
HNSCC affects over 500,000 patients worldwide annually and roughly half this number of patients will die from the disease each year (1) . Over the past several decades, there has been a rapid emergence of human papillomavirus-associated squamous cell carcinoma of the oropharynx (OPSCC), with a concomitant decline in smoking related OPSCC (1, 2) . These distinct types of OPSCC have different clinical presentation and response patterns to the standard treatment approaches including radiation and chemoradiotherapy, and this has led to different considerations in selecting the most appropriate treatment for HPV+ and HPV-patients (3) (4) (5) . Multiple studies have shown that the overall and disease-free survival for patients with HPV+ associated OPSCC is significantly better than for HPV-OPSCC patients (5, 6) . However, a group of HPV+ OPSCC patients' tumors remain refractory to conventional treatments with radiation given with or without chemotherapy and unusual patterns of recurrence and metastasis are emerging, particularly in patients with T4
and/or N3 staged disease (7) (8) (9) (10) . Therefore, new approaches to treatment of patients with high risk HPV+OSCC are needed. Thus, in the present study we have focused on a strategy to improve treatment of these patients by using a novel molecularly targeted agent to chemosensitize HPV + head and neck cancers.
Wee-1 is a serine/threonine kinase that has been linked to DNA damage induced G2-M arrest, owing to its ability to inactivate the cyclin dependent kinase 1 (CDK1), also known as CDC2, through phosphorylation of the Tyr15 residue (12) . Therefore, inhibition of the Wee-1 kinase activity can override a G2 cell cycle arrest and/or result in DNA damage by disrupting replication of the genome, leading to premature accumulation of cells with extensive DNA damage in mitosis and subsequent cell death through mitotic catastrophe (13, 14) . Recent work with AZD-1775 (formerly known as MK-1775), a specific inhibitor of Wee-1, and siRNA-mediated depletion indicates that Wee-1 inhibition abrogates the G2 checkpoint and selectively sensitizes tumor cells defective of p53 to various DNA-damaging agents, such as gemcitabine, cisplatin, and inhibits tumor growth in in vivo models (15) (16) (17) (18) . In light of the findings from these preclinical studies, AZD-1775 has entered phase I and II clinical trials as a chemosensitizer in patients with advanced solid tumors and shows good tolerability with minimal collateral cytotoxicity. We have recently, demonstrated that MK-1775 can overcome cisplatin resistance in HPV negative HNSCC cells expressing high risk mutant p53 through mitotic arrest followed by senescence rather than apoptosis (19) . Although, the status of p53 is predominantly wild type in HPV-positive HNSCC (20, 21) , the high-risk HPV E6 inactivates p53 through proteasomal degradation (22) . Therefore, it is possible that the defective p53 status in HPV+ HNSCC cells makes these tumors more vulnerable to chemosensitization upon Wee-1 kinase inhibition. Recent in vitro data have shown that HPV+ HNSCC cells and ovarian cell lines transfected with E6 oncoprotein are sensitive to Wee-1 kinase inhibition (18, 23, 24) . However, to our knowledge the single agent efficacy of AZD-1775 or in combination with cisplatin therapy has not been fully evaluated in vivo in high risk HPV+ HNSCC. In addition, it is not clear if AZD-1775 enhances the sensitivity of HPV+ HNSCC cells to cisplatin by mechanism(s) similar to that occurring in HPV negative HNSCC cells. In light of this information, we hypothesized that the Wee-1 kinase inhibitor, AZD-1775 will enhance the sensitivity of cisplatin both in vitro and in vivo in preclinical models of HPV+ oral cancer.
Our data show that AZD-1775 displays single-agent activity and significantly enhances the amino acids, and a vitamin solution, and incubated at 37°C in 5% CO 2 and 95% Air. HPV+ HNSCC cell lines stably expressing short hairpin RNA specific for p53 (shp53) were generated according to protocol described previously (25) . HPV+ HNSCC cell lines stably expressing MCl-1 were established using a pBabe-Flag h-MCl-1 vector (Addgene) as described previously (26) .The identity of all cell lines was authenticated using short tandem repeat testing within 6 months of cell use. The Wee-1 inhibitor, MK-1775 was initially provided by the Merck Corporation through a collaborative agreement arrange by NCI-CTEP. The drug is currently licensed by AstraZeneca and known as AZD-1775, and its chemical structure has been described previously (15) . 
Clonogenic survival assay
The HPV+HNSCC cells were seeded in 6-well plates at predetermined densities, concurrently exposed to different fixed-ratio combinations of cisplatin (dose range, 0.01-2 µmol/L) and AZD-1775 (dose range, 0.01-1µmol/L) for 24 hours and the clonogenic cell survival was determined as previously described (19) .
Analysis of combined drug effects
Drug synergy was determined by the combination-index and isobologram analyses, which were generated according to the median-effect method of Chou and Talalay (27) 
Antibodies
Antibodies used for Western blotting were phospho-γH2AX (Ser139; #2577), phospho-CDC2-Tyr15 (#9111), CDC2 (#9112), cyclin B1 (#4138), PARP-1 (#9542), MCl-1 (#4572), XIAP (#2042), Rad51 (#8875) and caspase-3 (#9661); all from Cell Signaling Technology; β-actin (#A5316; Sigma-Aldrich); p53(DO-1) (#sc-126) and MCl-1 (#sc-819) are from Santa Cruz; p21WAFI (Ab-1) (#OP64; Calbiochem); XIAP (#610716; BD Bioscience).
Western blot analysis
Cells grown on 10-cm plates were treated with clinically relevant doses of cisplatin (1.5 µmol/L), AZD-1775 (0.25 µmol/L) either alone or in combination for 16, 24 or 48 hours. For caspase cleavage detection, cells were pretreated with Z-VAD-FMK for 3 hours before addition of cisplatin and AZD-1775. Whole cell extracts were prepared and Western blot analysis was conducted with indicated antibodies as described previously (19, 25 (28) . The HPV-HNSCC (HN31) and HPV+ HNSCC (UMSCC47, HMS-001) cell lines were injected into the tongues of the male athymic nude mice and 8-10 days after injection mice were randomized into different groups. Treatment protocol and tumor growth delay measurement were conducted as previously described (19) , and a detailed description of the technique is included in the Supplementary Materials and Methods.
In vivo TUNEL assay
Apoptosis was assessed in mice tissue sections with terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay with DeadEnd 
Immunohistochemistry
Sections were prepared from formalin-fixed paraffin embedded mice tumor tissues and subjected to immunohistochemical staining with indicated antibodies according to the protocol as described in Supplementary Materials and Methods.
Statistical analysis
The Student t and a 1-Way ANOVA tests were carried out to analyze in vitro data. For mouse studies, a 2-Way ANOVA test was used to compare tumor volumes between control and treatment groups. For immunohistocemical analyses, a chi-square test was used to compare immunostaining between control and treatment groups. All data were expressed as mean ± standard error and P values <0.05 were considered significant. We next investigated whether Wee-1 kinase inhibition was synergistic with cisplatin treatment in the HPV+ HNSCC cell lines, using the combination index (CI) and fraction affected (Fa) method of Chou and Talalay (27) . Addition of AZD-1775 significantly enhanced the cytotoxic effect of cisplatin in these cells and the combination effect reveals strong synergism manifested by the shift of cisplatin response curves and the CI values < 1 (Fa 0.5, ± SD) of 0.14 ± 0.09, 0.15 ± 0.13, and 0.073 ± 0.07 ( Fig. 1D-1F , top plots) for UMSCC47, HB96 and HMS-001 respectively. The CI plots ( 13 from 49.27% to 11.05% within 48 hours in HMS-001 cells and from 60.71% to 31.48% within 72 hours in UMSCC47 cells ( Fig. 2A-B , and Supplementary Fig. S3A-S3B ). Abrogation of cisplatin-induced G2 checkpoint arrest and unscheduled mitosis were confirmed by the presence of increased phospho-H3 protein levels on Western blot (data not shown). Treatment with either AZD-1775 alone or AZD-1775 plus cisplatin led to an increase in the percentage of cells with sub-G1 DNA content at 48 and 72 hours, when compared to cisplatin alone for both UMSCC47 and HMS-001 cells ( Fig. 2A-B and Supplementary Fig. S3A-S3B ). By 72 hours the percent of UMSCC47 with sub-G1 DNA content following treatment with AZD-1775 alone or the combination was 44% and 38%, respectively, compared to just 10% in cisplatin treated cells. In HMS-001 cells, the highest percentage of sub-G1 DNA occurred after 72 hours combination treatment (71%), compared to AZD-1775 alone (54%) or cisplatin alone (36%). No polyploidy or micronuclei were observed in these cells upon the combination treatment, indicating an absence of mitotic catastrophe (data not shown). To investigate whether cells were dying through apoptosis, HPV+ (UMSCC47, HB96, HMS-001) and HPV-(HN30, HN31) HNSCC cells were treated with the drugs as previously indicted and cell lysates examined for PARP-1 protein cleavage 48 hours later .Consistent with our previous findings (19) , no PARP-1 cleavage was found in the HPV-HNSCC cell lines regardless of the drug treatments (Fig. 2C) . However, in both HPV+ cell lines, AZD-1775 alone induced PARP-1 cleavage that was even greater when combined with cisplatin (Fig. 2C) . The presence of apoptosis in HPV+ HNSCC cells was further confirmed with the positive APO-BrdU tunnel staining ( Fig. 2D and E) . In UMSCC47 the percentage of apoptotic cells was greatly enhanced by the combination treatment compared to AZD-1775 or cisplatin alone (69% versus 23% and 9.4%). However, HMS-001 cells were exquisitely sensitive to single agent AZD-1775, which induced apoptosis in greater than 90% of the population. This was consistent with high levels of PARP-1 cleavage observed in HMS-001 treated with AZD-1775 alone. Increased caspase-3/7 activity was observed at 24 hours in all HPV+ HNSCC cells following all treatments but was significantly greater in the combination of cisplatin and AZD-1775 versus single agents ( Supplementary Fig. S4A-S4B ). No increase in caspase-3/7 activity was observed in the HPV negative HNSCC cell lines ( Supplementary Fig. S4C-S4D ). Absence of caspase-dependent apoptosis in HPV-negative HNSCC cells was confirmed with western blotting (Supplementary Fig. S4E ).The increased caspasedependent activity could be blocked by the pan caspase inhibitor Z-VAD-FMK, demonstrating the specificity of the assay and the efficacy of the inhibitor. Treatment with Z-VAD-FMK profoundly inhibited the PARP-1 cleavage observed in HMS-001 exposed to AZD-1775 alone or in combination with cisplatin, confirming that PARP-1 cleavage was a consequence of drug induced caspase activation ( Supplementary Fig. S4F ). Collectively, these data indicate that AZD-1775 shows single agent activity and enhances cisplatin sensitivity in HPV+ HNSCC through caspase-mediated apoptosis. 
Results

AZD
AZD-1775 sensitizes HPV+ HNSCC cells to apoptosis in vitro
following all treatments (data not shown).
MCl-1 and XIAP are highly regulated anti-apoptotic proteins and inactivated through cleavage by caspase activation either in spontaneous apoptosis or in drug-induced programmed cell death (37, 38) .
To test for such possibility, the most sensitive HPV+ cells (HMS-001, HB96) were treated with cisplatin, AZD-1775 alone or in combination and MCl-1 and XIAP protein cleavage was examined by western blotting analysis. Appearance of MCl-1 and XIAP full-length and cleaved fragments was evident in these cells (Fig 3C-3E) . Additionally, the decrease in both MCl-1 and XIAP protein induced by treatment with AZD-1775 or AZD-1775 plus cisplatin could be prevented in HMS-001 cells by adding Z-VAD-FMK ( Supplementary Fig. 5SA ), indicating that the reduction of these anti-apoptotic proteins was most likely due to their cleavage following caspase activation. Further supporting this, appearance of cleaved MCl-1 bands on western blot after exposure to AZD-1775 alone or AZD-1775 combined with cisplatin was also inhibited by the pan caspase inhibitor (Supplementary Fig. S5B ).
Expression of MCl-1 and XIAP can be regulated at both the transcriptional and/or translational levels (37, 39, 40) . No changes in mRNA levels of MCl-1 and XIAP determined by qRT-PCR analysis were observed in HPV+ HNSCC cells treated with cisplatin, AZD-1775 or in combination ( Supplementary   Fig. S6A-S6B ), suggesting that AZD-1775 enhances the ability of cisplatin to regulate anti-apoptotic proteins levels through posttranslational rather than transcriptional regulation.
To investigate the role of decreased MCl-1 in apoptosis induced by exposure to AZD-1775 or its combination with cisplatin, Flag tagged MCl-1 protein was overexpressed in HPV+ HNSCC (HB96) cells ( Supplementary Fig. S6C ). Overexpression of MCl-1 inhibited PARP-1 cleavage induced by either AZD-1775 or the combination with cisplatin (Fig. 3F) , demonstrating that downregulation of the MCl-1 has a critical role in AZD-1775-induced apoptosis in HPV+ HNSCC tumors treated with cisplatin.
Research. 
CCR-15-0279
Knockdown of TP53 has no effect on the sensitivity of HPV+ HNSCC cells to cisplatin given alone or in combination with AZD-1775. A recent study reported that low levels of normally functioning wild type p53 remain in HPV+ HNSCC cells despite downregulation by the viral protein E6, and that this p53 can be activated by radiation therapy, leading to cell death through apoptosis (41) .Therefore, we examined if cisplatin alone or in combination with AZD-1775 sensitizes HPV+ HNSCC cells by reactivating p53 and its immediate primary target gene p21, leading to cell death.
While treatment with cisplatin alone increased p53 and p21 protein levels, addition of AZD-1775 did not further augment their protein levels in any of the HPV+ HNSCC cells tested (Fig 4A) . Use of a TP53-specific shRNA, but not control shRNA, led to significant reduction in p53 expression levels in UMSCC47 and undetectable in HB96 cell lines (Fig. 4B) . Therefore, the HB96 HPV+ HNSCC cell line was subsequently used for examining the role of wild type p53 on sensitivity to cisplatin in these cells. (Fig. 4C) . HPV+ HNSCC cells expressing shp53RNA showed survival fractions that were not different from those observed with control shRNA upon treatment with cisplatin and/or in combination with AZD-1775 (Fig. 4D) . Finally, we examined the effect of TP53-knockdown on apoptosis by detection of PARP-1 cleavage on Western blot analysis. No difference in PARP-1 cleavage was observed in control shRNA or shp53RNA HB96 cells following cisplatin alone or in combination with AZD-1775 (Fig. 4E) . These results suggest that the sensitization of HPV+ HNSCC Cells to cisplatin alone or in combination with AZD-1775 is not mediated through the p53 reactivation. into the tongues of nude mice as previously described (28) . Mice were treated with the drugs as described in Materials and Methods, and effects on tumor growth were examined. Cisplatin treated mice showed modest suppressive effects on tumor growth compared to untreated control groups ( Fig.   5A and B) . AZD-1775 alone showed significant growth inhibition compared to untreated mice (Fig. 5A and B, P < 0.001, P<0.0001 for UMSCC47 and HMS-001 respectively) but the difference from cisplatin treated mice was only significant in HMS-001 but not UMSCC47 bearing tumors (Fig. 5A and B, P<0.05). The combination of cisplatin and AZD-1775 significantly inhibited growth more than cisplatin treatment alone or control in tumors of mice bearing UMSCC47 and HMS-001HPV+ cells (Fig. 5A and   B ). Moreover, combination treatment showed modest effect on tumor growth inhibition over AZD-1775 alone in mice tumors carrying UMSCC47 cells (Fig. 5A , P = 0.07), but this effect was significant in mice bearing tumors with HMS-001 cells (Fig. 5B, P<0 .0001). Additionally, AZD-1775 monotherapy produced greater tumor growth inhibition in mice injected subcutaneously with HOSC19 HPV-positive patient-derived tumor xenografts (PDX) (Supplementary Fig. S7A ). To confirm that the enhancement of cisplatin antitumor efficacy by AZD-1775 was associated with engagement of downstream targets in vivo, phospho-CDK1 was evaluated in tissue sections obtained from tongue tumor xenografts. Consistent with earlier in vitro studies, AZD-1775 or its combination with cisplatin significantly decreased in vivo phospho-CDK1 immunostaining levels in orthotopic tongue tumors compared to cisplatin or untreated tumors (Fig. 5C-5F ). A decrease in phospho-CDK1 immunostaining was also observed in PDX tumors (HOSC19) (Supplementary Fig. S7B-S7C ). In addition, PCNA, a marker of proliferation, was significantly reduced in the UMSCC47 orthotopic tongue tumors from mice treated with either AZD-1775 or its combination with cisplatin compared to cisplatin alone or untreated control tumors ( Supplementary Fig. S8A and S8B, Chi-square, P < 0.0001). Immunostaining with the p16 antibody confirmed that HPV+ HNSCC cells maintained HPV-positivity in vivo ( Supplementary Fig   S8C) . Collectively, the results suggest that tumor growth inhibition is associated with decreased (Fig. 6A and B) , indicative of apoptosis and consistent with our in vitro results. Quantification of TUNEL-positive apoptotic cells shown in Fig 6A and B was presented as apoptotic index (Fig 6C and D) . Furthermore, MCl-1 and XIAP expression in tumor sections of UMSCC47 oral xenograft mice significantly decreased upon therapy with combination of cisplatin and AZD-1775 or AZD-1775 alone, compared cisplatin treated and control groups ( Fig. 6E and F We used a dose of 250 nmol/L which has been shown to achieve greater than 80% reduction in phosphorylation of the Wee-1 downstream target CDK1 (15, 19, 24, 42, 43) ; however, we have also observed apoptosis at much higher concentrations of the drug in p53 mutant HPV-HNSCC cells. (37, 38) , it is likely that the observed decrease in MCl-1 and XIAP was due to caspase-mediated processing after cisplatin and AZD-1775 treatment in HPV+ HNSCC. It has been previously shown that cleavage of MCl-1 and XIAP interferes with their antiapoptotic function in Jurkat and Hela cell lines (44, 45) . Correspondingly, we have demonstrated that both MCl-1 and XIAP are cleaved in response to treatment with AZD-1775 alone or in combination with cisplatin in HPV+ HNSCC cells. Furthermore, the downregulation of MCl-1 and its cleavage by AZD-1775 alone or in combination with cisplatin were completely attenuated by caspase inhibition, suggesting that MCl-1 and XIAP are targets of inactivation and degradation by caspase-3/7 in these cells. Additionally, caspase inhibition prevented apoptosis in these cells. We are not certain whether the degradation of Mcl-1 and XIAP we observed is a consequence of apoptosis or the cause of cell death phenotype. However, in our study, it is significant that enforced expression of MCl-1 markedly diminished AZD-1775-mediated PARP1 cleavage and apoptosis in HPV+ HNSCC (HB96) cells, suggesting that downregulation of antiapoptotic proteins is sufficient to trigger apoptosis. The mechanism by which AZD-1775 triggers the caspase-mediated apoptosis in these cells is not clear.
Evidence exists that, in response to DNA damage, activation of several procaspases is required before mitochondrial permeabilization and apoptosis can take place (46, 47) . In light of this evidence, it is possible that Wee-1 inhibition further augments cisplatin-mediated DNA damage response, followed by casapse activation, cleavage of MCl-1 and XIAP, leading to apoptotic cell death in HPV+HNSCC.
This possibility is supported by our time course experiments which revealed that the DNA damage occurred at 8 hours and preceded caspase 3/7 activation observed at 24 hours post treatment.
Alternatively, the primary downstream target of Wee-1, the CDK1 may directly induce caspase activation in HPV+ HNSCC cells.
Functionally, the E6 viral oncoprotein of HPV inactivates wild type p53 and inhibits apoptosis (48) .
Our data revealed that complete knockdown of TP53 by shRNA did not affect clonogenic cell survival and did not block apoptosis in HPV+ HNSCC treated with cisplatin or in combination with AZD-1775.
This finding indicates that reactivation of p53 is not sufficient to sensitize HPV+ HNSCC to cisplatin treatment combined with Wee-1 kinase inhibition and are not in agreement with recent published data which showed that knockdown of p53 resulted in radiation resistance in HPV+ HNSCC (41) . It is possible that reactivation of p53 has different roles depending on the type of genotoxic therapy.
Potentially, HPV E6 has additional effects other than inactivation of p53 that augment sensitivity to cisplatin and AZD-1775 in HPV+ HNSCC. Probably, HPV+ cells have greater deficiency repairing the DNA damage upon cytotoxic treatment, predisposing them to cell death by apoptosis. Interestingly, both E6 and E7 are involved in activation and repression of DNA damage response pathways to support viral genome maintenance and amplification in the normal viral life cycle (49) . A recent study has also shown that E6 and E7 o activate caspases-3-7, and -9 upon differentiation to induce viral genome amplification (50) . Understanding of how these alterations contribute to DNA damage response to cisplatin and Wee-1 kinase inhibition will warrant future investigations. 
